XBiotech Inc.
NASDAQ:XBITBiotechnology
-$0.02 today
- Market cap
- $52.74M
- Beta
- 0.84
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.32
Volume 0.06M
Average 0.03M
XBIT Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
XBiotech Inc.NASDAQ: XBIT
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin dips below year-ago levels
Q1 FY2026 selling, general & admin of $1.07M fell 44.7% year over year, behind the +32.3% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 75.7% from the prior quarter. Over 3 fiscal years it compounded at +9.6% a year.
Context
- Selling, general & admin increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether next quarter's selling, general & admin reaches the consensus estimate of $7.12M, a +611.6% change from the same quarter last year.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $1.07M-75.7% QoQ
- Last fiscal yearDec 2025
- $8.3M+76.0% YoY
- LTMMar 2026
- $7.43M+32.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -44.7% | +611.6% | +656.3 pp |
| 1 year | +76.0% | — | — |
| 3-year CAGR | +9.6% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 8.3M USD
- Year-over-year change
- +76.0%
- 4-year CAGR
- -3.0%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.3M | +76.0% |
| FY2024 | 2024-12-31 | 4.71M | +1.1% |
| FY2023 | 2023-12-31 | 4.66M | -26.1% |
| FY2022 | 2022-12-31 | 6.31M | -32.8% |
| FY2021 | 2021-12-31 | 9.39M | — |
Selling, General & Admin vs competitors
How XBIT compares with its peers on the latest reported figures
- XBIT's LTM Mar 2026 selling, general & admin of $7.43M is the 8th highest of the 9 companies compared; the peer median is $21.31M.
- Its year-over-year change of +32.3% is the 2nd highest of 8, against a peer median of -8.4%.
- Over three fiscal years its annual growth of +9.6% compares with a peer median of -4.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $86.8M | -8.8% | -5.3% | 131.2% | |
| LTM Mar 2026 | $37.33M | +8.8% | -81.3% | — | |
| LTM Mar 2026 | $30.56M | -0.6% | +16.3% | 334.5% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $22.61M | -10.5% | +40.4% | — |
| LTM Mar 2026 | $20M | -29.6% | -4.4% | — | |
| LTM Mar 2026 | $8.98M | -8.4% | -3.8% | — | |
| LTM Jun 2024 | $7.81M | — | -15.8% | 957.8% | |
| LTM Mar 2026 | $7.43M | +32.3% | +9.6% | — | |
| LTM Apr 2026 | $7.21M | +72.5% | +21.3% | 400.3% | |
| Peer median (excluding XBIT) | $21.31M | -8.4% | -4.1% | 367.4% | |
Competitors are the stored peer set for XBIT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 18.39M | 4.01M | 0 | 0 | 0 |
| Cost of Revenue | 5.82M | 651K | 0 | 0 | 1.69M |
| Gross Profit | 12.57M | 3.36M | 0 | 0 | (1.69M) |
| Gross Margin | 68.4% | 83.8% | — | — | — |
| Research & Development | 28.27M | 31.54M | 32.85M | 37.76M | 47.39M |
| Selling, General & Admin | 9.39M | 6.31M | 4.66M | 4.71M | 8.3M |
| Operating Expenses | 37.66M | 37.85M | 37.51M | 42.47M | 54M |
| Depreciation & Amortization | 2.65M | 2.61M | 1.74M | 1.75M | 1.69M |
| EBITDA | (22.81M) | (30.97M) | (22.57M) | (36.01M) | (43.53M) |
| EBITDA Margin | -124.0% | -772.4% | — | — | — |
| Operating Income | (25.08M) | (34.49M) | (37.51M) | (42.47M) | (55.69M) |
| Operating Margin | -136.4% | -860.1% | — | — | — |
| Interest Income | 467K | 3.82M | 10.42M | 9.81M | 5.68M |
| Interest Expense | 0 | 0 | 0 | 807K | 88K |
| Other Income / Expenses | (376K) | 902K | 13.2M | 3.91M | 10.38M |
| Income Before Tax | (25.46M) | (33.59M) | (24.31M) | (38.56M) | (45.31M) |
| Pre-Tax Margin | -138.4% | -837.6% | — | — | — |
| Income Tax Expense | (8.04M) | (688K) | 244K | (32K) | 235K |
| Net Income | (17.41M) | (32.9M) | (24.56M) | (38.53M) | (45.54M) |
| Net Margin | -94.7% | -820.4% | — | — | — |
| EPS (Basic) | (0.58) | (1.08) | (0.81) | (1.26) | (1.49) |
| EPS (Diluted) | (0.58) | (1.08) | (0.81) | (1.26) | (1.49) |
| Weighted Avg Shares | 30.04M | 30.44M | 30.32M | 30.46M | 30.49M |
| Weighted Avg Shares (Diluted) | 30.04M | 30.44M | 30.44M | 30.46M | 30.49M |
XBiotech Inc.
NASDAQ:XBIT
Intrinsic Alpha fair value
Locked
Current Price
$1.73
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.